Get the Daily Brief
Latest Biotech News
Lilly Outpaces Novo Nordisk in Oral GLP-1 Diabetes Trial; FDA Filing Pending
Eli Lilly reported that its oral GLP-1 candidate orforglipron surpassed Novo Nordisk’s Rybelsus in a Phase 3 diabetes trial, lowering HbA1c more and producing greater weight loss. The highest dose...
Atyr Pharma’s Lead Lung Drug Fails Phase 3 Trial, Shares Collapse
Biotech aTyr Pharma announced that its Phase 3 trial of efzofitimod failed to meet the primary endpoint of reducing steroid use in pulmonary sarcoidosis patients. The drug showed a modest,...
CSL Secures $117M Option to Acquire Dutch Blood Clotting Drug Developer VarmX
CSL Ltd. invested $117 million to acquire an exclusive option to purchase VarmX BV, a developer of VMX-C001, a Phase 3-ready drug targeting blood coagulation reversal in patients on Factor Xa...
Ollin Biosciences Launches with $100M, Targets Roche’s Eye Drug Market
Ophthalmologist Jason Ehrlich launched Ollin Biosciences with $100 million in funding to develop novel antibody therapeutics aimed at eye diseases. The company's lead bispecific antibody, OLN324,...
Regeneron Reports Positive Phase 3 Data for Rare Skeletal Disease Drug
Regeneron Pharmaceuticals announced a pivotal Phase 3 trial success for garetosmab, a drug for fibrodysplasia ossificans progressiva (FOP), an ultra-rare condition causing abnormal bone formation....
AI Advances Enable Cardiovascular Risk Prediction from Mammograms
Researchers at The George Institute for Global Health have developed a machine learning algorithm that analyzes routine mammograms to accurately predict cardiovascular disease (CVD) risk in women....
New CRISPR-Based Oral Test Promises Faster, Non-Invasive TB Detection
Tulane University researchers developed ActCRISPR-TB, a novel CRISPR-Cas12a assay capable of detecting Mycobacterium tuberculosis DNA from tongue swabs within an hour. The single-pot, isothermal...
Areteia Therapeutics’ Oral Asthma Drug Meets Primary Endpoint in Phase 3 Trial
Areteia Therapeutics reported positive Phase 3 results for dexpramipexole, an oral small molecule targeting eosinophilic asthma. The Exhale-4 trial met its primary endpoint, showing significant...
Novartis Expands Immunology Pipeline with Monte Rosa Molecular Glue Deal
Novartis has deepened its collaboration with Monte Rosa Therapeutics by agreeing on a new partnership worth up to $5.7 billion to develop multiple molecular glue degraders targeting...
aTyr Pharma’s Efzofitimod Fails Phase 3 Trial in Pulmonary Sarcoidosis
aTyr Pharma’s experimental drug efzofitimod did not meet its primary endpoint in a Phase 3 study aiming to reduce oral steroid use in patients with pulmonary sarcoidosis. Despite some promising...
Lilly Selects Virginia for $5B API Bioconjugate Manufacturing Facility
Eli Lilly has chosen West Creek Business Park near Richmond, Virginia, to build a $5 billion manufacturing plant dedicated to producing active pharmaceutical ingredients (APIs) for monoclonal...
US Pharma Investment Retreats From UK Amid Regulatory and Pricing Uncertainty
Major pharmaceutical companies including AstraZeneca, Merck, and Eli Lilly have withheld or halted planned investments totaling hundreds of millions of dollars in the UK life sciences sector....
New CRISPR-Based Oral Swab Test Enhances Tuberculosis Detection
Researchers at Tulane University have developed ActCRISPR-TB, a novel CRISPR-Cas12a assay enabling rapid, sensitive detection of Mycobacterium tuberculosis DNA from a simple tongue swab. This...
AI and Deep Learning Platforms Accelerate Drug Discovery and Precision Oncology
Artificial intelligence is increasingly embedded in biopharma, with innovative AI platforms transforming drug discovery and precision medicine. Stanford Medicine unveiled CRISPR-GPT, an AI...
Lila Sciences Raises $235 Million for AI-Powered Autonomous Research Labs
Lila Sciences, a startup developing AI-driven autonomous research labs to accelerate scientific discovery, has secured $235 million in Series A funding. The company aims to create 'scientific...
Mount Sinai Opens AI Research Lab for Cardiac Catheterization Advances
Mount Sinai Fuster Heart Hospital has launched The Samuel Fineman Cardiac Catheterization Artificial Intelligence Research Lab, integrating cutting-edge AI algorithms with cardiology expertise to...
Breakthroughs in Alzheimer’s Disease: New Blood Tests and Therapeutics
Recent advances in Alzheimer’s research highlight new diagnostic and therapeutic frontiers. Novel blood tests improve early detection of amyloid and tau pathologies, facilitating timely diagnosis...
Novartis Expands Protein Degrader Collaboration with Monte Rosa – $5.7 Billion Deal
Novartis and Monte Rosa Therapeutics have entered an expanded research collaboration worth up to $5.7 billion, advancing molecular glue degraders for immune-mediated diseases. This new agreement...
Pharma Firms Freeze UK R&D Amid Drug Pricing Turmoil – AstraZeneca, Sanofi, Merck Pull Back
AstraZeneca paused its $271 million Cambridge expansion, completing a withdrawal from its $884 million UK investment package amid frustrations with government support and pricing policies. Sanofi...
Atyr Pharma's Efzofitimod Fails Phase 3 Pulmonary Sarcoidosis Trial – Shares Plunge
Atyr Pharma reported that efzofitimod did not achieve its primary endpoint of steroid dose reduction in a Phase 3 trial involving pulmonary sarcoidosis patients. While some secondary outcomes...